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Abstract
Objective: Reports of low sexual activity rates and high impairment rates among women with chronic diseases have not
included comparisons to general population data. The objective of this study was to compare sexual activity and
impairment rates of women with systemic sclerosis (SSc) to general population data and to identify domains of sexual
function driving impairment in SSc.
Methods: Canadian women with SSc were compared to women from a UK population sample. Sexual activity and, among
sexually active women, sexual impairment were evaluated with a 9-item version of the Female Sexual Function Index (FSFI).
Results: Among women with SSc (mean age= 57.0 years), 296 of 730 (41%) were sexually active, 181 (61%) of whom were
sexually impaired, resulting in 115 of 730 (16%) who were sexually active without impairment. In the UK population sample
(mean age= 55.4 years), 956 of 1,498 women (64%) were sexually active, 420 (44%) of whom were impaired, with 536 of
1,498 (36%) sexually active without impairment. Adjusting for age and marital status, women with SSc were significantly less
likely to be sexually active (OR= 0.34, 95%CI = 0.28–0.42) and, among sexually active women, significantly more likely to be
sexually impaired (OR= 1.88, 95%CI = 1.42–2.49) than general population women. Controlling for total FSFI scores, women
with SSc had significantly worse lubrication and pain scores than general population women.
Conclusions: Sexual functioning is a problem for many women with scleroderma and is associated with pain and poor
lubrication. Evidence-based interventions to support sexual activity and function in women with SSc are needed.
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Introduction
Systemic sclerosis (SSc), or scleroderma, is a chronic, multi-
system, connective tissue disorder characterized by abnormal
fibrotic processes and excessive collagen production, which
manifests itself in skin thickening and fibrosis of internal organs
[1]. Approximately 80% of SSc patients are women, with highest
onset rates between ages 30–60 [2]. Common causes of disability
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include limitations in physical mobility, pain, fatigue, depressive
symptoms, and body image distress from disfigurement [3–8].
In the general population, sexual activity and impairment rates
are, among other factors, highly associated with age and marital
status [9,10]. For instance, in a large population study of over
3,000 women from the metropolitan Boston area, the adjusted
odds of being sexual active were approximately 3 times as high for
women in the 30–39 age group than for women aged 50–59.
Among sexually active women, on the other hand, the odds of
impairment were more than 3 times as high in women 50–59 as
among women 30–39. The odds of sexual activity among married
women were approximately 6 times the odds for unmarried
women, although married women who were active were more
likely to be sexually impaired compared to sexually active
unmarried women.
In women with SSc, physical and psychological consequences of
the disease, including fatigue, depression, disfigurement, Ray-
naud’s phenomenon, skin tightening and discomfort, vaginal
tightness and dryness, thickening of skin around the lips, painful
finger ulcers and calcium deposits, gastrointestinal symptoms, joint
pain and muscular weakness, may affect sexual function [11–16].
A recent study found that only 41% of 547 female SSc patients in
the Canadian Scleroderma Research Group (CSRG) Registry
reported sexual activity in the past 4 weeks [12]. Over 60% of
sexually active patients reported impaired sexual function based on
the short version of the Female Sexual Function Index (FSFI)
[12,17]. Overall, only 17% of patients were sexually active without
impairment. In multivariate analysis, women who were sexually
active were significantly more likely to be younger, and to have
fewer gastrointestinal symptoms and less severe Raynaud’s
phenomenon symptoms. Women who were sexually impaired
were significantly more likely to be older and to have greater skin
involvement and more severe breathing problems. Disease
duration was unrelated to sexual activity and impairment.
Limited sexual activity and impaired sexual function appear to
be common among women with many chronic illnesses [18],
including SSc [11,12,19–23]. We do not know of any studies,
however, that have compared activity and impairment rates
among women with a chronic illness to general population data.
Thus, the objectives of this study were to 1) compare sexual
activity and impairment rates, stratified by age and marital status,
between women with SSc and women from a population sample;
2) estimate the overall odds of being sexually active and of
experiencing impairment for women with SSc compared to the
population sample, controlling for age and marital status; and 3)
identify domains of sexual function most strongly related to
impairment in women with SSc.
Methods
There are no Canadian population studies that have used the
FSFI to assess sexual activity and impairment. Thus, this study
involved a secondary analysis of existing databases of women with
SSc from the CSRG Registry and a general population sample
from the Adult Twins UK registry [9].
Ethics Statement
Ethics approval for the present study was obtained from the
Research Ethics Board of the Jewish General Hospital, Montreal,
Canada. The CSRG Registry was approved by the McGill
University Institutional Review Board and the research ethics
boards of each participating CSRG site. All CSRG Registry
patients provided informed written consent. The sexual function-
ing study for the Twins UK sample was approved by the St.
Thomas’ Hospital Research Ethics Committee and all participants
provided informed written consent.
SSc Patient Sample
Female patients from 12CSRG Registry sites from across
Canada completed study questionnaires between July 2008 and
February 2012. Eligible Registry patients are $18 years old, have
a rheumatologist-confirmed diagnosis of SSc, and are fluent in
English or French. At annual Registry visits, patients undergo
extensive clinical evaluations and complete self-report question-
naires, including questions on sexual function.
UK Population Sample
This sample consisted of monozygotic and dizygotic female twin
individuals enrolled in the Adult Twins UK Registry who
completed the FSFI in 2008 [24]. Registry participants were
recruited through successive national media campaigns in the
United Kingdom and Ireland and from other twin registers,
including the Aberdeen Twin Registry and the Institute of
Psychiatry Adult Registry. The Twins UK sample has been found
to be similar to other UK female population samples in terms of
disease prevalence and lifestyle characteristics [25–27].
Measures
Sexual Activity. In the CSRG Registry, women were
classified as sexually active/inactive based on the question, ‘‘During
the past 4 weeks, have you engaged in sexual activities with your partner?’’ In
the UK population sample, rather than a single question,
classification was made based on the response ‘‘no sexual activity’’
in the past 4 weeks, which was included as a response on 7 FSFI
questions (of 9 total FSFI questions).
Sexual Impairment. Studies on female sexual function have
been criticized for coding sexually inactive women as impaired
[28]. Thus, in both samples, sexual impairment was only assessed
among sexually active women. A 9-item abbreviated version [12]
of the 19-item FSFI, which assesses sexual activity and functioning
over the past 4 weeks [17] was used. The 9-item abbreviated
version includes items assessing 5 dimensions of sexual function,
including desire (2 items), arousal (1 item), lubrication (1 item),
orgasm (3 items), and pain (2 items). We included women who
responded to items from all domains, and who were missing #1
item from any domain and #3 items total.
Items on the FSFI are scored from 1–5 with the exception of 2
items related to pain during and following vaginal intercourse,
which are scored 0 if vaginal intercourse was not attempted. The
original FSFI has good reliability and validity and differentiates
between women with and without sexual dysfunction diagnoses
[17,29–31]. A 10-item abbreviated version correlated highly with
the original 19-item version (r=0.98) in a sample of 568 women
[10,29]. The only difference between the 10-item version and the
9-item version used in this study is that the 9-item version included
2 pain items, rather than 3. In previous studies, the 3 pain items
produced substantively identical mean scores and very high
estimates of internal consistency (3-item Cronbach’s alpha = 0.94–
0.98) [17,29–31], suggesting item redundancy and that weighted
total scores of the 9-item and 10-item versions would be
comparable since the difference in number of items is adjusted
for by domain weighting. To obtain a full-score on the FSFI,
domain scores are weighted and summed [12,17]. A cut-off score
of 22.5 was used to classify impairment/non-impairment. This
cut-off effectively differentiates women with and without sexual
dysfunction based on DSM-IV criteria [10].
Sexual Satisfaction. Sexual satisfaction was assessed among
sexually active women using the question, ‘‘Over the past 4 weeks, how
Female Sexual Functioning in Systemic Sclerosis
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satisfied have you been with your overall sex life?’’ Responses were on a 1–
5 scale from ‘‘very satisfied’’ to ‘‘very dissatisfied’’.
Marital Status. In the CSRG Registry, women were
classified as married if they indicated being married or living as
married. In the UK population sample, women were classified as
married if they indicated being married or being in a relationship
and living with their partner.
Education level. Education level obtained was based on self-
report and classified as ‘‘# High School’’ or ‘‘. High School.’’ In
the CSRG sample, patients identified the highest level of
education they had received and responses were dichotomized
as ‘‘# High School’’ or ‘‘. High School.’’ In the UK population
sample, participants identified the number of years of schooling
they had received, and a cut-off of 11 years was used to
dichotomize responses as ‘‘# High School’’ or ‘‘. High School’’.
Clinical characteristics (CSRG sample only). Time since
SSc diagnosis and time from first non-Raynaud’s disease
manifestation were recorded by study physicians. Skin involve-
ment was assessed using the modified Rodnan skin score [32], a
widely used clinical assessment where the examining rheumatol-
ogist records the degree of skin thickening from 0 (no involvement)
to 3 (severe thickening) in 17 body areas (total score range 0–51).
Patients were classified into limited and diffuse cutaneous subsets
based on Leroy’s definition [33].
Data Analyses
The percentages of women with SSc and women from the
general UK population who reported being sexually active were
calculated, and rate ratio analyses were conducted, stratified by
age group and marital status. Among those reporting being
sexually active, rates of sexual impairment (FSFI total #22.5) were
compared similarly across samples by age and marital status.
Multivariate logistic regression analyses were used to assess the
independent contributions of sample group (CSRG or UK general
population), age in years and marital status to sexual activity status
and impairment status. Post-hoc analyses including education level
as an additional variable in the regression models were also
performed. In addition, separate multivariate logistic models were
run to compare the subset of patients with limited SSc versus the
general population sample, and then the subset of patients with
diffuse SSc versus the general population sample.
Discrimination and calibration of the logistic regression models
were assessed with the c-index and Hosmer-Lemeshow goodness-
of-fit test statistic (HL), respectively [34]. The c-index is the
percentage of comparisons where sexually active (or sexually
impaired) patients had a higher predicted probability of being
sexually active (or sexually impaired) than inactive patients (or
non-impaired patients), for all possible pairs of active and inactive
patients (or impaired and non-impaired patients). The HL is a
measure of the accuracy of the predicted number of cases of active
or impaired patients compared to the number of patients who
actually reported sexual activity or impairment across the
spectrum of probabilities. A relatively large p value indicates that
the model fits reasonably well.
In order to identify areas of sexual function that are particularly
problematic for women with SSc, sexual domain scores were
calculated among women who were sexually active, and analysis of
covariance was used to assess the differences in each sexual
domain score between women with SSc and women from the
general population sample, controlling for total FSFI scores.
Analyses were also performed using Pearson’s correlations to
determine the correlation between domain scores for the domains
that were found to have significantly worse scores among women
with scleroderma compared to the general population. This was
done to assess the degree to which important problem areas for
women with SSc seemed to represent general disease severity
versus specific problems that may be independent of each other.
Finally, among sexually active women in both samples, Pearson’s
correlations were used to assess the association between FSFI total
and individual sexual domain scores and sexual satisfaction.
All analyses were conducted using SPSS version 20.0 (Chicago,
IL), and statistical tests were 2-sided with a P,0.05 significance
level.
Table 1. Comparison of sociodemographic and clinical characteristics of women with systemic sclerosis and women from a UK
general population sample.
Sociodemographic Characteristics
Systemic Sclerosis
Patients (N=730)
UK General Population
Sample
(N=1,498) P Value
Age in years, mean (standard deviation) 57.0 (11.3) 55.4 (11.5) 0.001
Education, n (%): ,0.001
# High School 356 (49) 992 (66)
. High School 373 (51) 344 (23)
Not reported 1 (0.1) 162 (11)
Marital Status, n (%): ,0.001
Married or Living as Married 505 (69) 877 (59)
Not Married 225 (31) 621 (41)
Clinical Characteristics
Time since non-Raynaud’s symptom onset in years, mean (standard deviation)(N = 720) 12.8 (9.7) ----------
Time since diagnosis of SSc in years, mean (standard deviation)(N = 722) 10.0 (8.6) ----------
Modified Rodnan skin score, mean (standard deviation)(N = 706) 8.0 (8.4) ----------
Diffuse SSc, n (%)(N = 681) 171 (25) ----------
doi:10.1371/journal.pone.0052129.t001
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Results
Sample Characteristics
There were 800 women with SSc and 1,589 women from the
UK general population sample who completed questionnaires. Of
these, 44 women with SSc and 84 from the UK did not indicate
their sexual activity status. Among sexually active women, 16 with
SSc and 7 from the UK did not have complete data for sexual
impairment analyses. A further 10 women with SSc did not
indicate their marital status. Thus, there were 730 women with
SSc (91%) and 1,498 women from the UK (94%) with complete
data included in analyses.
Sociodemographic characteristics for both samples and clinical
characteristics for the SSc sample can be found in Table 1. The
SSc sample had a mean age of 57.0 (SD=11.3; range 18–83), and
the UK sample had a mean age of 55.4 (SD=11.5; range 25–82;
p = 0.001). Almost 70% of women with SSc were married,
compared to just under 60% in the UK sample (p,0.001).
Women with SSc were also more likely to have at least high school
education (p,0.001). Among women with SSc, 75% had limited
cutaneous SSc, and mean time since onset of non-Raynaud’s
symptoms was approximately 10 years.
Women with SSc who were not included in analyses due to
missing data (n = 70) were slightly older (mean age 61.7,
SD=13.2), less likely to be married (62% married), and less likely
to have at least a high school education (34% . high school
education), compared to women with complete data, but had
similar clinical characteristics. Among women in the UK sample,
women who were not included in analyses (n = 91) were, similarly
to in the SSc sample, older (mean age 65.5, SD=9.3), less likely to
be married (46% married), and less likely to have at least a high
school education (18% . high school education).
Overall, 296 women with SSc (41%) were sexually active, 181
(61%) of whom were sexually impaired. In the population sample,
956 women (64%) were sexually active, 420 (44%) of whom were
sexually impaired. Thus, taken as a whole, 115 of 730 women with
SSc (16%) were sexually active without impairment, compared to
536 of 1,498 of women from the UK general population sample
(36%).
Sexual Activity in SSc Compared to Population Sample
Rates of sexual activity, stratified by age group and marital
status, are presented in Table 2. There were relatively few women
with SSc in the 18–29 and 30–39 age groups for both married and
unmarried women. Among all other age group/marital status
combinations, women with SSc were significantly less likely to be
sexually active than women from the UK population sample.
In multivariate logistic regression analysis, older age was
significantly associated with a lower likelihood of sexual activity
(odds ratio [OR]= 0.94, 95% confidence interval [CI] = 0.93–
0.94, P,0.001), while those who were married were more likely to
be sexually active (OR=2.21, 95% CI=1.82–2.68, P,0.001).
Controlling for age and marital status, women with SSc were
significantly less likely to be sexually active than women from the
general population sample (OR=0.34, 95% CI= 0.28–0.41,
P,0.001). The model had adequate discriminative power (c-
index = 0.742) and calibration (P= 0.288 for the HL statistic).
In post-hoc sensitivity analyses, women with more than a high
school education level were significantly more likely to be sexually
active (OR=1.26, 95% CI= 1.02–1.57, P=0.035). Inclusion of
the education variable in the modeldid not substantively influence
the assocation of any of the other variables in the core model with
sexual activity. When separate models were run for patients with
limited and diffuse SSc, patients with limited SSc were significantly
less likely to be sexually active than women from the general
population sample (OR=0.33, 95% CI=0.26–0.42, P,0.001),
controlling for age and marital status, as were patients with diffuse
SSc (OR=0.37, 95% CI= 0.27–0.53, P,0.001).
Sexual Impairment in SSc Compared to Population
Sample
Rates of sexual impairment (among sexually active women)
stratified by age group and marital status, can be found in Table 3.
There were small numbers of women with SSc in each age group
who were unmarried, as well as small numbers who were married
and under age 40. For each age group of married women aged 40
and above, women with SSc were significantly more likely to be
sexually impaired than women from the UK population sample.
In multivariate logistic regression analysis among sexually active
women, older women were more likely to be sexually impaired,
(OR=1.05, 95% CI= 1.04–1.06, P,0.001), as were those who
were married (OR=1.41, 95% CI=1.09–1.82, P= 0.009).
Controlling for age and marital status, women with SSc were
significantly more likely to be sexually impaired than women from
the general population sample (OR=1.88, 95% CI= 1.42–2.49,
P,0.001). The model had adequate discriminative power (c-
index= 0.668) and calibration (P= 0.190 for the HL statistic).
When education was included in the model, women with more
than a high school education level were significantly more likely to
be sexually impaired (OR=1.40, 95% CI= 1.07–1.84, P=0.015).
Inclusion of the education variable in the model, however, did not
substantively influence the assocation of any of the other variables
in the core model with sexual impairment. Patients with limited
SSc were significantly less likely to be sexually active than women
from the general population sample (OR=1.97, 95% CI= 1.41–
2.75, P,0.001), controlling for both age and marital status, as
were patients with diffuse SSc (OR=2.15, 95% CI= 1.32–3.51,
P= 0.002).
Comparison of Sexual Domains in SSc and Population
Sample
Differences in sexual domain scores between women with SSc
and women from the population sample, unadjusted and adjusted
for total FSFI score, can be found in Table 4. For all domains of
sexual functioning, women with SSc had significantly worse scores,
indicating greater impairment, than women from the general
population. Controlling for total FSFI scores, pain and lubrication
scores were significantly worse for women with SSc. Pain and
lubrication scores were more highly correlated amongst women
with SSc (r = 0.62, P,0.001) than among women from the
population sample (r = 0.36, P,0.001).
Correlations of FSFI domain scores with sexual satisfaction
scores for the SSc sample and the general population sample can
be found in Table 5. For all sexual domains and for the FSFI total
score, correlations with sexual satisfaction were substantially
higher among women with SSc than among women from the
population sample.
Discussion
This is the first study to compare rates of sexual activity and
function in a sample of women living with a serious chronic disease
to women from a general population sample. Although the SSc
sample was from Canada and the general population sample was
from the UK, the results were sufficiently robust to be confident
that, controlling for age and marital status, women with SSc were
significantly less likely to be sexually active and significantly more
likely to be sexually impaired than women from a general
Female Sexual Functioning in Systemic Sclerosis
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population sample. This finding consistently held across groups
stratified by age and marital status. When women with SSc and
women from the general population with similar sexual impair-
ment scores were compared, women with SSc had significantly
worse lubrication and pain scores. Overall sexual satisfaction was
more highly associated with impairment ratings among women
with SSc compared to women from the general population
sample. There are many factors that may influence sexual
satisfaction, some of which are related to health status and
impairment and others that are not. This finding suggests that
factors related to sexual impairment were more important in the
scope of overall sexual satisfaction in SSc than in the general
population, whereas other factors may play a larger role.
Low rates of sexual activity and high rates of sexual impairment
are commonly reported in women with chronic diseases [18],
including SSc [11,12,19–23]. However, no previous studies had
compared rates to those from a general population sample using a
validated method of assessment. Thus, the extent to which rates
among women with chronic diseases, including SSc, were different
from the general population was not clear.
We know of two large general population studies that have used
the FSFI to separately estimate rates of sexual activity and
impairment [9,10]. One of these two studies comprised the sample
of women in the UK that was used in the present study [9]. In this
sample, 64% of women were sexually active, and among sexually
active women, 44% were sexually impaired, resulting in 36% who
were active without impairment. The other large population study
was a sample of 3,205 women from the Boston metropolitan area
[10]. In this study, 51% were sexually active, and 38% of those
sexually active were sexually impaired, resulting in 32% sexually
active without impairment [10]. In both general population
studies, rates of sexual activity and impairment were strongly
associated with age and marital status [9,10]. Neither study,
however, published data in a form that allowed direct comparison
of published results, disaggregated by age and marital status,
between women from the general population and women with
scleroderma. We were able to obtain the original data from the
twins study for the present study because the data were publically
available in a post-study repository.
An important contribution of the current study was that it is the
first study to directly compare sexual activity and impairment
among women with a chronic medical disease to women from a
general population sample, using original data from both samples
and controlling for both age and marital status. Another important
contribution is that it directly compared sexual functioning
domains among women with SSc to general population women.
Table 2. Comparison of sexual activity rates between women with systemic sclerosis and women from a UK general population
sample, stratified by age and marital status.
Married Non-Married
CSRG UK CSRG UK
Age
Group N
N (%)
Active N
N (%)
Active
Rate
Ratio 95% CI N
N (%)
Active N
N (%)
Active
Rate
Ratio 95% CI
18–29 5 4 (80) 8 5 (63) 1.28 0.64–2.56 8 2 (25) 10 8 (80) 0.31 0.09–1.08
30–39 18 12 (67) 91 81 (89) 0.75 0.54–1.05 13 7 (54) 65 52 (80) 0.67 0.40–1.13
40–49 103 71 (69) 143 119 (83) 0.83 0.71–0.96 36 14 (39) 110 88 (80) 0.49 0.32–0.74
50–59 171 92 (54) 294 220 (75) 0.72 0.62–0.84 52 9 (17) 186 117 (63) 0.28 0.15–0.50
60–69 156 62 (40) 263 140 (53) 0.75 0.60–0.93 79 10 (13) 172 78 (45) 0.28 0.15–0.51
70+ 52 11 (21) 78 34 (44) 0.49 0.27–0.87 37 2 (5) 78 14 (18) 0.30 0.07–1.26
Total 505 252 (50) 877 599 (68) 0.73 0.66–0.81 225 44 (20) 621 357 (57) 0.34 0.26–0.45
doi:10.1371/journal.pone.0052129.t002
Table 3. Comparison of sexual impairment rates between women with systemic sclerosis and women from a UK general
population sample, stratified by age and marital status.
Married Non-Married
CSRG UK CSRG UK
Age
Group N
N (%)
Impaired N
N (%)
Impaired
Rate
Ratio 95% CI N
N (%)
Impaired N
N (%)
Impaired
Rate
Ratio 95% CI
18–29 4 3 (75) 5 4 (80) 0.94 0.46–1.92 2 0 (0) 8 1 (13) 0 -----
30–39 12 7 (58) 81 23 (28) 2.05 1.14–3.71 7 5 (71) 52 14 (27) 2.65 1.39–5.07
40–49 71 36 (51) 119 41 (34) 1.47 1.05–2.06 14 5 (36) 88 16 (18) 1.96 0.86–4.51
50–59 92 60 (65) 220 112 (51) 1.28 1.05–1.56 9 6 (67) 117 52 (44) 1.50 0.91–2.48
60–69 62 45 (73) 140 79 (56) 1.29 1.04–1.59 10 5 (50) 78 42 (54) 0.93 0.48–1.78
70+ 11 8 (73) 34 26 (76) 0.95 0.63–1.43 2 1 (50) 14 10 (71) 0.70 0.17–2.91
Total 252 159 (63) 599 285 (48) 1.33 1.17–1.50 44 22 (50) 357 135 (38) 1.32 0.96–1.83
doi:10.1371/journal.pone.0052129.t003
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In SSc, several previous studies have suggested that rates of sexual
impairment might be high using different instruments and
methods, and have suggested factors that may be related
[11,12,19–23]. No previous studies, however, used a validated
measure to compare domains of sexual function that may be
problematic for women with SSc. The finding of the present study
that lubrication is a key problem driving impairment in SSc is
consistent with literature suggesting that vaginal dryness is
commonly reported among women with SSc, and is linked to
sexual impairment [11,13,23]. In addition, the finding that pain
was also an important factor driving impairment in SSc is
consistent with previous research, which found that over 60% of
sexually active female SSc patients report experiencing pain
during sexual activity, and almost 40% report experiencing pain
after sexual activity [12].
In addition to symptomatic treatments for SSc symptoms,
including vasodilators for Raynaud’s syndrome and finger ulcers,
proton pump inhibitors and promotility agents for gastric reflux,
and general analgesia (e.g., acetaminophen, anti-inflammatories
when not contra-indicated, and narcotics if necessary), several
authors have suggested steps that women with SSc can take that
may reduce their pain and discomfort during sexual activity
[11,13,14]. For instance, a water-based lubricant may be useful to
reduce vaginal dryness and dyspareunia [11,13,14,19,20,23]. A
warm bath before sexual activities, attempting alternative sexual
positions, and using pillows may reduce the effects of painful joints
[11,14,20,22]. Good communication during sexual activity has
also been emphasized so that partners are aware of what is
pleasurable and painful [14]. It is also possible that sexual function
could be improved through range of motion exercises to reduce
joint pain and stiffness prior to sexual activity, massage or exercises
to lessen mouth tightening and improve mouth function, and
massage or gentle manual stretching to lessen vaginal tightness.
The degree to which these suggestions are effective in reducing
barriers to sexual activity and enhancing the sexual experience of
women with SSc, however, has not been tested.
There are a number of limitations that should be considered in
interpreting the results of our study. First, it was cross-sectional
and conducted with a convenience sample of patients enrolled in
the CSRG Registry. Patients with very severe SSc who were too
sick to participate, as well as those who may have died earlier in
their disease course, are not enrolled in the Registry, which may
result in an over-representation of healthier patients. Although
approximately 80% of approached patients enroll in the Registry,
data on patients who do not participate are not available. Second,
the non-medical, population sample of the Adult Twins Registry is
from a different country than that of the CSRG Registry, which
could influence comparability. Third, the non-medical, population
sample was from a twin registry. However, there is no reason to
expect that a twin sample would bias results, and there are no
other readily available population samples to make any attempt at
benchmarking the levels of activity and impairment from SSc.
Additionally, the Adult Twins Registry has been shown to be
representative of the general population for a wide range of
Table 4. Comparison of FSFI domain scores between sexually active women with systemic sclerosis Patients and sexually active
women from a UK general population sample; unadjusted and adjusted for total FSFI score.
Unadjusted Domain Scores Domain Scores, Adjusted for Total FSFI Score
FSFI Domain
Mean Difference
(UK – CSRG) P value Hedge’s g
Mean Difference
(UK – CSRG) P value Hedge’s g
Desire 0.29 ,0.001 0.25 20.11 0.054 20.13
Arousal 0.22 0.014 0.16 20.31 ,0.001 20.38
Lubrication 0.94 ,0.001 0.66 0.40 ,0.001 0.43
Orgasm 0.36 0.001 0.25 20.19 0.003 20.20
Pain 0.75 ,0.001 0.46 0.21 0.012 0.17
(CSRG Sample: N = 296; UK Sample: N = 956).
doi:10.1371/journal.pone.0052129.t004
Table 5. Correlations of FSFI domain scores with sexual satisfaction scores among sexually active women with systemic sclerosis
and sexually active women from a UK general population sample.
CSRG Sample (N=294) UK Population Sample (N=947)
FSFI Domain Correlation 95% CI P value Correlation 95% CI P value
Desire 0.61 0.53–0.68 ,0.001 0.42 0.37–0.47 ,0.001
Arousal 0.68 0.61–0.74 ,0.001 0.51 0.46–0.56 ,0.001
Lubrication 0.50 0.41–0.58 ,0.001 0.34 0.28–0.40 ,0.001
Orgasm 0.70 0.64–0.75 ,0.001 0.51 0.46–0.56 ,0.001
Pain 0.42 0.32–0.51 ,0.001 0.30 0.24–0.36 ,0.001
Total FSFI score 0.74 0.68–0.79 ,0.001 0.57 0.53–0.61 ,0.001
doi:10.1371/journal.pone.0052129.t005
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lifestyle and sexual behavioural factors [26,27]. Thus, although
this comparison does not permit strong claims about precise
estimates of the risk of non-activity and dysfunction in SSc, it
provides a general context and allows for a global understanding of
the degree of sexual impairment from SSc compared to non-
medically ill women. In both studies, women indicated if they had
been sexual active or not, but no definition for the term ‘‘sexual
activity’’ was provided. Thus, it is possible that this term may have
been interpreted differently by different women. For instance, it is
possible that some may have considered aspects such as hugging,
snuggling, kissing and touching to be sexual activities, whereas
others may have considered sexual activity to be defined solely as
some form of penetration. Another limitation is that the 9-item
version of the FSFI has not been specifically validated, although it
has been used previously in SSc [12]. Furthermore, we do not
know to what degree having sexual problems may have influenced
whether or not women were married, however this would apply
across both samples in this study. Finally, while there were missing
data in both samples, the proportion of missing data was very low
in both samples (9% in SSc and 6% in the UK sample), and the
relatively small differences in the characteristics of women with
complete data and those with missing data were consistent across
samples.
In summary, sexual impairment is a problem for many women
living with scleroderma. Adjusting for age and marital status,
women with SSc were less than half as likely to be sexually active
and, among sexually active women, almost twice as likely to be
sexually impaired than women in the general population. Overall,
only 16% of women with SSc were sexually active without
impairment, compared to 36% in the general population.
Controlling for total FSFI scores, women with SSc had signifi-
cantly worse pain and lubrication scores than women in the
general population. Research is needed to develop interventions to
target pain and lubrication problems, specifically, and to improve
overall sexual functioning among women with this disease.
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